Two Years Of Artificial Intelligence Deals: A Pharma Snapshot
INFOGRAPHIC: major alliance deals focused on artificial intelligence and machine learning, signed by pharmaceutical companies over the past two years.
You may also be interested in...
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.
Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally.